Abstract:Ambroxol, a commonly used mucolytic agent, has been extensively studied for its clinical effectiveness in managing respiratory conditions in pediatric and adult patients. The existing body of research on ambroxol demonstrates its safety and efficacy. However, its potential role in preventing and treating neonatal diseases still needs to be explored. This scoping review aims to shed light on the unexplored potential of ambroxol, particularly its applications in perinatal and neonatal care. We aim to offer valuable insights for healthcare professionals, researchers, and academics, thus presenting a positive perspective. Key scientific databases such as Google Scholar, PubMed, Cochrane Library, and Europe PMC were meticulously searched for relevant literature on ambroxol in perinatal and neonatal medicine. Gray literature was also surveyed, and the search encompassed all study designs and languages up to June 2024. Furthermore, citations and reference lists of relevant articles were scrutinized to identify additional pertinent literature. Ambroxol has demonstrated promising effects in preventing and managing respiratory distress syndrome (RDS). It can enter the placental circulation and rapidly build up in human lung tissue to a much greater extent than in plasma. It promotes fetal lung maturation, surfactant production, and alveolar expansion. Numerous studies have demonstrated the efficacy of antenatal and postnatal ambroxol in the prevention and treatment of RDS. Ambroxol has the potential to be administered intravenously or through nebulization, offering the hopeful possibility of reducing the high failure rate typically associated with non-invasive ventilation in extremely preterm infants, instilling a sense of hope and optimism about the potential of ambroxol. It also shows potential in treating bronchopulmonary dysplasia, meconium aspiration syndrome, and neonatal infections. Ambroxol has been observed to assist in the closure of patent ductus arteriosus in preterm infants by inhibiting vasodilator agents such as nitric oxide and exerting vasoconstrictive properties. However, these biological actions may raise concerns regarding the potential induction of pulmonary hypertension and an increased risk of necrotizing enterocolitis. The present scoping review also examines the clinical evidence and the potential of ambroxol in reducing the incidence of intraventricular hemorrhage in preterm infants. Ambroxol may have potential analgesic properties in managing neonatal pain, and as it can penetrate the blood-brain barrier, it suggests potential neuroprotective properties. These properties may encompass the modulation of microglial activation and the antagonistic impact on glutamate receptors. Ambroxol's attributes could contribute to a decreased susceptibility to neurological complications and have demonstrated anticonvulsant effects in preclinical studies. While low-to-moderate-quality evidence indicates potential applications of ambroxol in neonatal care, further research is needed to determine the drug's optimal dosing, timing, and safety profiles in this patient population. We need to investigate ambroxol's potential synergistic effects with antenatal steroids. Exploration is required to assess ambroxol's potential in reducing the high failure rate associated with non-invasive respiratory support for RDS. Lastly, comprehensive studies on the long-term neurodevelopmental outcomes of neonates exposed to ambroxol are essential.

Ambroxol with High Frequency Oscillation on Neonatal Meconium Aspiration Syndrome

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

Clinical effect of large dose of ambroxol in treatment of acute episode of chronic bronchitis (AECB)

[Use of Noninvasive High-Frequency Oscillatory Ventilation in Very Low Birth Weight Infants].

Clinical Efficacy of Preferred Use of High-Frequency Oscillatory Ventilation in Treatment of Neonatal Pulmonary Hemorrhage

Effect of High Dose Ambroxo1 on the Time of Weaning from Mechanical Ventilation of Patients with ARDS in ICU

A randomized single‐center controlled trial of synchronized intermittent mandatory ventilation with heliox in newborn infants with meconium aspiration syndrome

Therapeutic effect of micropump intravenous infusion of ambroxol hydrochloride on respiratory distress syndrome in premature infants

Aerosol Inhalation of Ambroxol for Pneumonia: A Systematic Review

Different dose of ambroxol on acute exacerbation of chronic obstructive pulmonary disease in elderly patients

Clinical Study of Inhaled Ambroxol in the Adjunctive Treatment of Lower Respiratory Tract Infection Induced by Pseudomonas Aeruginosa

The application of ambroxol hydrochloride combined with fiberoptic bronchoscopy in elderly patients with severe pneumonia: A meta-analysis and systematic review

The Potential of Ambroxol as a Panacea for Neonatal Diseases: A Scoping Review

Lung-protective Effect of Perioperative Treatment with Ambroxol in the Elderly Lung Cancer Patients

EFFECT OF AMBROXOL IN THE PATIENTS WITH CODP AND RESPIRATORY FAILURE DURING MECHANICAL VENTILATION

Adjunctive Treatment of Bronchiectasis Infection with Ambroxol and Sodium Bicarbonate Through Sequential Lavage: an Efficacy Analysis

Advances in the Management of Meconium Aspiration Syndrome

Experience for the treatment of large dose of ambroxol applied in multi-drug resistant bacterial pneumonia

Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty

Prevention of bronchopulmonary complications by ambroxol after thoracotomy in patients with chronic obstructive pulmonary disease

Effect of Nasal Continuous Positive Airway Pressure on Infants With Meconium Aspiration Syndrome: A Randomized Clinical Trial